There was a numerical trend in favor of the combination therapy with palbociclib and AI for rwPFS, but not for OS 36 .
← all excerpts
Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer.
1
—
—